The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | Venetoclax + pirtobrutinib for MCL resistant to CAR-T and targeted therapies
Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a recent publication on a study evaluating the combination of venetoclax plus pirtobrutinib in PDX mouse models with mantle cell lymphoma (MCL) resistant to targeted and CAR-T therapy. Improved survival was observed, and enrolment has begun for a clinical trial investigating this combination. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
